Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 394

1.

In-silico analysis of Thr767Ile pathogenic variant in the MSH6 gene in family with endometrial cancer.

Stembalska A, Klapecki J, Pławski A, Karpinski P.

Eur J Obstet Gynecol Reprod Biol. 2019 Jul;238:54-57. doi: 10.1016/j.ejogrb.2019.04.035. Epub 2019 Apr 22.

PMID:
31100584
2.

A novel heterozygous large deletion of MSH6 gene in a Chinese family with Lynch syndrome.

Liu Y, Wang M, Chen Q, Zheng Q, Li G, Cheng Q, Liu S, Ye S.

Gene. 2019 Jul 1;704:103-112. doi: 10.1016/j.gene.2019.04.011. Epub 2019 Apr 8.

PMID:
30974197
3.

MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.

Evensen NA, Madhusoodhan PP, Meyer J, Saliba J, Chowdhury A, Araten DJ, Nersting J, Bhatla T, Vincent TL, Teachey D, Hunger SP, Yang J, Schmiegelow K, Carroll WL.

Haematologica. 2018 May;103(5):830-839. doi: 10.3324/haematol.2017.176362. Epub 2018 Feb 15.

4.

Polymorphism of Gly39Glu (c.116G>A) hMSH6 is associated with sporadic colorectal cancer development in the Polish population: Preliminary results.

Zelga P, Przybyłowska-Sygut K, Zelga M, Dziki A, Majsterek I.

Adv Clin Exp Med. 2017 Dec;26(9):1425-1429. doi: 10.17219/acem/64877.

5.

Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.

Sun Q, Pei C, Li Q, Dong T, Dong Y, Xing W, Zhou P, Gong Y, Zhen Z, Gao Y, Xiao Y, Su J, Ren H.

Biochem Biophys Res Commun. 2018 Feb 19;496(4):1040-1046. doi: 10.1016/j.bbrc.2018.01.093. Epub 2018 Jan 31.

PMID:
29366782
6.

Incomplete Segregation of MSH6 Frameshift Variants with Phenotype of Lynch Syndrome.

Liccardo R, De Rosa M, Rossi GB, Carlomagno N, Izzo P, Duraturo F.

Int J Mol Sci. 2017 May 6;18(5). pii: E999. doi: 10.3390/ijms18050999.

7.

The polymorphisms of MSH6 gene are associated with AIDS progression in a northern Chinese population.

Wang C, Zhao C, Zhang X, Xu L, Jia X, Sun H, Yu J, Zhang G, He N, Li Q, Qiao Y, Fu S.

Infect Genet Evol. 2016 Aug;42:9-13. doi: 10.1016/j.meegid.2016.04.016. Epub 2016 Apr 16.

PMID:
27090025
8.

[A Family Affected by Lynch Syndrome Caused by MSH6 Germline Mutation].

Chika N, Kumamoto K, Suzuki O, Fukuchi M, Matsuzawa T, Kumagai Y, Ishibashi K, Eguchi H, Mochiki E, Ishida H.

Gan To Kagaku Ryoho. 2015 Nov;42(12):2211-4. Japanese.

PMID:
26805314
9.

Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas.

Graham RP, Kerr SE, Butz ML, Thibodeau SN, Halling KC, Smyrk TC, Dina MA, Waugh VM, Rumilla KM.

Am J Surg Pathol. 2015 Oct;39(10):1370-6. doi: 10.1097/PAS.0000000000000459.

PMID:
26099011
10.

Constitutional mismatch repair-deficiency and whole-exome sequencing as the means of the rapid detection of the causative MSH6 defect.

Hoell JI, Gombert M, Ginzel S, Loth S, Landgraf P, Käfer V, Streiter M, Prokop A, Weiss M, Thiele R, Borkhardt A.

Klin Padiatr. 2014 Nov;226(6-7):357-61. doi: 10.1055/s-0034-1389905. Epub 2014 Nov 28.

PMID:
25431869
11.

Identification of a novel MSH6 germline variant in a family with multiple gastro-intestinal malignancies by next generation sequencing.

Connor AA, Katzov-Eckert H, Whelan T, Aronson M, Lau L, Marshall C, Charames GS, Pollett A, Gallinger S, Lerner-Ellis J.

Fam Cancer. 2015 Mar;14(1):69-75. doi: 10.1007/s10689-014-9765-9.

PMID:
25380764
12.

hMSH6: a potential diagnostic marker for oral carcinoma in situ.

Jessri M, Dalley AJ, Farah CS.

J Clin Pathol. 2015 Jan;68(1):86-90. doi: 10.1136/jclinpath-2014-202411. Epub 2014 Oct 28.

PMID:
25352643
13.

Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.

Pemov A, Sung H, Hyland PL, Sloan JL, Ruppert SL, Baldwin AM, Boland JF, Bass SE, Lee HJ, Jones KM, Zhang X; NISC Comparative Sequencing Program, Mullikin JC, Widemann BC, Wilson AF, Stewart DR.

PLoS Genet. 2014 Oct 16;10(10):e1004575. doi: 10.1371/journal.pgen.1004575. eCollection 2014 Oct.

14.

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Sep 15;20(18):4894-903. doi: 10.1158/1078-0432.CCR-13-1856. Epub 2014 Jul 30.

15.

High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma.

Alvino E, Passarelli F, Cannavò E, Fortes C, Mastroeni S, Caporali S, Jiricny J, Cappellini GC, Scoppola A, Marchetti P, Modesti A, D'Atri S.

Am J Clin Pathol. 2014 Jul;142(1):121-32. doi: 10.1309/AJCPCX2D9YULBBLG.

16.

Association between MSH6 G39E polymorphism and cancer susceptibility: a meta-analysis of 7,046 cases and 34,554 controls.

Li Z, Kong L, Yu L, Huang J, Wang K, Chen S, Yu M, Wei S.

Tumour Biol. 2014 Jun;35(6):6029-37. doi: 10.1007/s13277-014-1798-z. Epub 2014 Mar 13.

PMID:
24622885
17.

DNA mismatch repair gene MSH6 implicated in determining age at natural menopause.

Perry JR, Hsu YH, Chasman DI, Johnson AD, Elks C, Albrecht E, Andrulis IL, Beesley J, Berenson GS, Bergmann S, Bojesen SE, Bolla MK, Brown J, Buring JE, Campbell H, Chang-Claude J, Chenevix-Trench G, Corre T, Couch FJ, Cox A, Czene K, D'adamo AP, Davies G, Deary IJ, Dennis J, Easton DF, Engelhardt EG, Eriksson JG, Esko T, Fasching PA, Figueroa JD, Flyger H, Fraser A, Garcia-Closas M, Gasparini P, Gieger C, Giles G, Guenel P, Hägg S, Hall P, Hayward C, Hopper J, Ingelsson E; kConFab investigators, Kardia SL, Kasiman K, Knight JA, Lahti J, Lawlor DA, Magnusson PK, Margolin S, Marsh JA, Metspalu A, Olson JE, Pennell CE, Polasek O, Rahman I, Ridker PM, Robino A, Rudan I, Rudolph A, Salumets A, Schmidt MK, Schoemaker MJ, Smith EN, Smith JA, Southey M, Stöckl D, Swerdlow AJ, Thompson DJ, Truong T, Ulivi S, Waldenberger M, Wang Q, Wild S, Wilson JF, Wright AF, Zgaga L; ReproGen Consortium, Ong KK, Murabito JM, Karasik D, Murray A.

Hum Mol Genet. 2014 May 1;23(9):2490-7. doi: 10.1093/hmg/ddt620. Epub 2013 Dec 19.

18.

Molecular and clinical characteristics of MSH6 germline variants detected in colorectal cancer patients.

Terui H, Tachikawa T, Kakuta M, Nishimura Y, Yatsuoka T, Yamaguchi K, Yura K, Akagi K.

Oncol Rep. 2013 Dec;30(6):2909-16. doi: 10.3892/or.2013.2781. Epub 2013 Oct 2.

PMID:
24100870
19.

DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.

Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A.

J Clin Endocrinol Metab. 2013 Mar;98(3):1130-6. doi: 10.1210/jc.2012-2924. Epub 2013 Jan 30.

PMID:
23365123
20.

Benzo[α]pyrene repressed DNA mismatch repair in human breast cancer cells.

Chen Y, Huang C, Bai C, Gao H, Ma R, Liu X, Dong Q.

Toxicology. 2013 Feb 8;304:167-72. doi: 10.1016/j.tox.2013.01.003. Epub 2013 Jan 11.

PMID:
23313663

Supplemental Content

Support Center